|
|
||||||||
Eur J Cardiothorac Surg 2006;29:585-590
© 2006 Elsevier Science NL
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
Received 28 October 2005; received in revised form 20 December 2005; accepted 22 December 2005.
* Corresponding author. Tel.: +81 95 849 7304; fax: +81 95 849 7306. (Email: nagayasu{at}net.nagasaki-u.ac.jp).
| Abstract |
|---|
|
|
|---|
Key Words: Bronchoplasty Broncho-angioplasty Lung cancer
| 1. Introduction |
|---|
|
|
|---|
| 2. Patients and methods |
|---|
|
|
|---|
60% of predicted value) [11]. Table 1
shows the clinical characteristics of the bronchoplasty and the broncho-angioplasty groups.
|
The type of pulmonary arterioplasty depended on the resected area of the PA: if up to 1/2 of the PA circumference was resected, then angioplasty with patch grafts (patch plasty) was performed; and if over 1/2 of the PA circumference was resected, then a sleeve resection with end-to-end anastomoses (sleeve plasty) was performed. In the 29 angioplasty patients, there were 12 patch plasties and 17 sleeve plasties.
2.2 Surgical technique
Single-lung ventilation was established through a double-lumen endotracheal tube. A routine posterolateral thoracotomy in the fifth intercostal space was done. Mediastinal and hilar lymph node dissection was routinely performed, and frozen sections of all bronchial margins were carefully examined. The bronchial anastomoses were done using an interrupted suture technique with monofilament absorbable 4-0 sutures and were wrapped with a pericardial fat pad, omentum, or mediastinal pleura, as described elsewhere [12]. Suturing of the pulmonary artery was done using a running suture technique with monofilament nonabsorbable 5-0 sutures. Ringed or patchy expanded polytetrafluoroethylene grafts (Gore-Tex, USA) were used for the sleeve or patch plasty procedures. We washed the anastomosis sites with diluted heparin to prevent intraluminal thrombosis, but systemic heparin was not used intraoperatively or postoperatively.
2.3 Perioperative evaluation
Preoperative staging routinely included chest X-rays, computed tomography of the chest and upper abdomen, bronchoscopy, upper abdominal ultrasonography, magnetic resonance imaging of the cerebrum, and bone scintigraphy. A pulmonary angiogram was performed in selected cases. After the anastomoses were completed, postoperative bronchoscopy was performed routinely in the operating room, as well as 2 weeks following surgery, 36 months after discharge, and whenever anastomotic complications were suspected. Patients were followed up by routine chest X-rays and chest computed tomography after discharge. Operative morbidity or mortality was defined as the occurrence of complications or death within 90 days of the operation.
2.4 Statistical analysis
All results are expressed as mean ± standard error. Categorical data were calculated as percentages and compared using the
2-test. Patient survival rates were calculated by life-table analysis. KaplanMeier curves were plotted and compared using the log-rank test for univariate analysis. Multivariate analyses of independent prognostic factors were assessed by the Cox proportional hazards stepwise model using StatView V (SAS Institute Inc., Cary, NC, USA). Statistical significance was set at p
< 0.05. Results are presented as the estimated relative risk with corresponding 95% confidence intervals. The study protocol was approved by the Human Ethics Review Committee of Nagasaki University School of Medicine and a signed consent form was obtained from each subject.
| 3. Results |
|---|
|
|
|---|
In the broncho-angioplasty group, 4 (13.8%) patients were stage I (1 IA and 3 IB), 6 (20.7%) were stage II (6 IIB), 12 (41.4%) were stage IIIA, and 7 (24.1%) were stage IIIB. T4 disease involved the superior vena cava (n = 4) and aorta (n=1), as well as a separate tumor nodule in the same lobe (n = 2). The nonsquamous cell carcinoma included adenocarcinoma (n = 6) and large cell carcinoma (n = 1).
Of the 147 patients, a preoperative respiratory risk was present in 32 (21.8%), of whom 26 (22.0%) were in the bronchoplasty group and 6 (20.7%) in the broncho-angioplasty group.
Overall, 31 patients had adjuvant or neoadjuvant therapy. In the bronchoplasty group, of the 23 (19.5%) patients who had adjuvant or neoadjuvant therapy, 11 had neoadjuvant chemotherapy, 8 had adjuvant chemotherapy, 2 had adjuvant radiotherapy, and 2 had adjuvant chemo-radiotherapy. In the broncho-angioplasty group, of the 8 (27.6%) patients who had adjuvant or neoadjuvant therapy, 1 had neoadjuvant chemotherapy, 3 had adjuvant chemotherapy, 3 had adjuvant radiotherapy, and 1 had adjuvant chemo-radiotherapy.
The 90-day postoperative morbidity rate was 23.8% (35 of 147 patients) overall, 22.9% (27 of 118 patients) in the bronchoplasty group, and 27.6% (8 of 29 patients) in the broncho-angioplasty group (p = 0.5953). The 90-day postoperative mortality rate was 8.2% (12/147) overall, 5.9% (7/118) in the bronchoplasty group, and 17.2% (5/29) in the broncho-angioplasty group (p = 0.047) (Table 2 ).
|
In the broncho-angioplasty group, two patients were suspected of having minor bronchopleural fistulas based on chest X-rays and bronchoscopy. Both of these patients with a bronchopleural fistula were observed and improved, but one patient who had undergone right uppermiddle sleeve lobectomy with S6 segmentectomy and PA sleeve plasty died from contralateral pneumonia on day 46. The other patient who had undergone left upper sleeve lobectomy with shaving of aortic adventitia and PA sleeve plasty died from perforation of the aorta on day 65. A patient who had a right upper sleeve lobectomy with resection of the chest wall and PA sleeve plasty died on postoperative day 8 from an unexpected bronchovascular fistula. The two cases from both groups who died from a bronchovascular fistula had surgery in 1986 and did not undergo wrapping for their bronchial anastomoses. Since 1990, all patients in the broncho-angioplasty group had wrapping for their anastomoses, mainly using the pericardial fat pad. Pulmonary artery occlusion occurred in one patient who had undergone left upper sleeve lobectomy with PA sleeve plasty. Left completion pneumonectomy was performed on the fourth postoperative day, but the patient died as a result of a bronchopleural fistula on day 58. Another patient who had undergone right upper sleeve lobectomy with PA patch plasty died from pulmonary embolism on day 62. Other complications were managed conservatively in most cases.
3.1 Factors affecting survival
The median follow-up for all patients was 26.6 months (8 days to 174.8 months). The overall 5-year survival for all patients was 56.0%. There was a significant difference in the 5-year survival between the bronchoplasty group (63.4%) and the broncho-angioplasty group (24.2%, p
= 0.0003). Among patients with stage I or II, the 5-year survival was 76.2% for the bronchoplasty group and 51.9% for the broncho-angioplasty group (p
= 0.1791; Fig. 1
). Among patients with stage IIIA, IIIB, or IV, there was a significant difference in 5-year survival between the bronchoplasty group (43.5%) and the broncho-angioplasty group (7.9%, p
= 0.0192; Fig. 2
).
|
|
70 years), gender, preoperative respiratory risk, type of operation (bronchoplasty vs broncho-angioplasty), adjuvant or neoadjuvant therapy, postoperative complications, histologic type (squamous cell carcinoma vs nonsquamous cell carcinoma), pT status (pT1 or T2 vs T3 or T4), and pN status (pN0 or N1 vs N2 or N3). Significant risk factors associated with poor survival included use of the broncho-angioplastic procedure, the incidence of postoperative complications, nonsquamous cell histologic type, pT3 or T4, and pN2 or N3. Table 3 shows the results of the multivariate analysis of the independent prognostic factors. The data indicate that the type of operation, postoperative complications, histologic type, and pN status are significant factors affecting survival. The pT status showed a trend, but it was not statistically significant.
|
| 4. Discussion |
|---|
|
|
|---|
Ever since early 1980, when our institution reported a small series of lung cancer patients who had undergone bronchoplasty, we have been performing bronchoplasties in lung cancer patients to effectively preserve pulmonary parenchyma and control the disease [16]. In this paper covering the period from 1985 to 2004, 11.6% (163/1405) of the patients who underwent lung resections for primary lung cancer had bronchoplastic procedures. Compared to other reports [6,14,15], this rate is relatively high, as our data includes 29 cases with combined PA reconstruction. Despite data that support the use of bronchoplasty as compared to pneumonectomy, so far there have been only a few small series that have evaluated broncho-angioplasty [810]. In our series, the overall survival rate for bronchoplasty patients was 63.4%, which is higher than that in other recent reports [46,10,15,17]. In contrast, the overall survival rate for patients undergoing broncho-angioplasty was not satisfactory, as it was similar to the rate reported in pneumonectomy patients [46]. However, when the results of broncho-angioplastic resection are examined in patients with stage I or II disease, it is seen that long-term survival is similar or superior to that after bronchoplasty [46,1315]. This result indicates that broncho-angioplasty can be a valuable alternative to pneumonectomy in stage I or II, and may be considered as an alternative to pneumonectomy in stage III or IV only when pneumonectomy is contraindicated due to poor cardiopulmonary function.
The overall 30-day postoperative mortality was 4.1% (6/147), which was lower or similar to that of previous reports [2,6]. However, the overall 90-day postoperative mortality rate increased to 8.2% (12/147); 17.2% (5/29) in the broncho-angioplasty group and 6% (7/118) in the bronchoplasty group. Six of the 12 cases of 90-day postoperative deaths related to insufficient anastomoses (four with a bronchopleural fistula and two with a bronchovascular fistula) and occurred early in the time period of this series. Wada et al. [9] demonstrated that, in the postoperative management of broncho-angioplasty, there was a high incidence of severe postoperative complications; therefore, utmost caution is required in the postoperative management of such patients. In the present series since 1996, no 30- or 90-day postoperative deaths occurred after sleeve lobectomy with or without angioplasty. It should be emphasized that the improvement in the healing process of the bronchial anastomosis contributed more than postoperative management to the prevention of fatal anastomotic insufficiency. Therefore, to promote healing, we have been combining several individual techniques, such as tissue coverage of the bronchial anastomoses with the pedunculated pericardial fat pad or omentum [12], telescope anastomosis [18], simple interrupted suture combined with figure-of-eight suture [19], and preserving the bronchial arterial branches [20].
Despite intraoperative confirmation of the safety margin by frozen sections, local tumor recurrence always has to be considered as a major postoperative complication after bronchoplasty or broncho-angioplasty. In their review, Tedder et al. [2] found that the local recurrence rate for sleeve lobectomy was 13%, and in other recent series, the local recurrence rate has ranged from 8% to 22% [4,5,17]. During the follow-up period in our series, the incidence of local recurrence at the site of first occurrence was 17.2% (5/29) in the broncho-angioplasty group and 7% (8/118) in the bronchoplasty group. Local recurrence was more frequent in the broncho-angioplasty group; however, three of the five patients in this group had pN2 disease. Thus, it was difficult to determine whether local recurrence truly occurred from the site of bronchoplasty or whether the patient had regional lymph nodal involvement.
In most of the other series, multivariate analysis has shown that long-term survival in patients treated with bronchoplasty or broncho-angioplasty was influenced mainly by the nodal stage or advanced tumor stage [10,11,17]. End et al. [11] showed that the presence of respiratory or cardiovascular risk was associated with a poor outcome along with advanced tumor stage and the type of bronchoplastic procedure; however, their data included a small number of sleeve pneumonectomy cases with a 25% 1-year survival. In the current series, the presence of nonsquamous cell carcinoma on histology, advanced nodal status, broncho-angioplasty, and postoperative complications were all risk factors for a poor outcome, whereas the preoperative respiratory risk and adjuvant therapy were not significant risk factors. We suspect that one possible reason for this is that the rate of pN2 or N3 disease was higher in patients with nonsquamous cell carcinoma (20/37) than in patients with squamous cell carcinoma (30/110).
In conclusion, both bronchoplasty and broncho-angioplasty are useful in the treatment of lung cancer and should be performed as an alternative to pneumonectomy in patients with stage I or II disease. However, careful patient selection is mandatory in patients with an advanced tumor stage and with nonsquamous cell carcinoma. As well, utmost caution is needed in broncho-angioplasty cases, as postoperative complications tend to be fatal.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. Venuta, A. M. Ciccone, M. Anile, M. Ibrahim, T. De Giacomo, G. F. Coloni, and E. A. Rendina Reconstruction of the pulmonary artery for lung cancer: Long-term results J. Thorac. Cardiovasc. Surg., November 1, 2009; 138(5): 1185 - 1191. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nakanishi, S. Oka, and S. Odate Video-assisted thoracic surgery major pulmonary resection requiring control of the main pulmonary artery Interactive CardioVascular and Thoracic Surgery, October 1, 2009; 9(4): 618 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ma, A. Dong, J. Fan, and H. Cheng Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 20 - 28. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |